

Reference number(s)
2222-A

Specialty Guideline Management

Parsabiv

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Parsabiv	etelcalcetide

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indication¹

Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- Serum calcium levels
- Intact parathyroid hormone (iPTH) levels

Reference number(s)
2222-A

Prescriber Specialties

This medication must be prescribed by or in consultation with an endocrinologist or a nephrologist.

Coverage Criteria

Secondary Hyperparathyroidism with CKD on Hemodialysis¹⁻⁷

Authorization of 12 months may be granted for treatment of secondary hyperparathyroidism in a member with chronic kidney disease (CKD) on hemodialysis who meets the following criteria:

- Member has a serum calcium level (corrected for albumin) greater than or equal to 8.4 mg/dL (see Appendix).
- Member has an intact parathyroid hormone (iPTH) level above the normal range as defined by the laboratory reference value.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when the member is experiencing benefit from therapy as evidenced by a decrease in intact parathyroid hormone (iPTH) levels from pretreatment baseline.

Appendix⁶

Corrected calcium = measured total calcium + 0.8(4.0 – serum albumin)

References

1. Parsabiv [package insert]. Thousand Oaks, CA: Amgen, Inc.; January 2025.
2. Micromedex Solutions [database online]. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: www.micromedexsolutions.com. Accessed October 15, 2025.
3. AHFS DI (Adult and Pediatric) [database online]. Lexi-Comp, Inc. Hudson, OH. Available at: http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed October 15, 2025.

Reference number(s)
2222-A

4. Clinical Pharmacology [Internet]. Elsevier. Tampa (FL). Available at: <http://www.clinicalpharmacology.com>. Accessed October 15, 2025.
5. Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. *JAMA*. 2017;317(2):146-155.
6. Shoback D. Hypoparathyroidism. *NEJM*. 2008;359: 391-403.
7. Smit MA, Kinschot CMJ, Linden JVD, et al. Clinical guidelines and PTH measurements: Does assay generation matter? *Endocrine Review*. 2019; 40 (6): 1468-1480.